Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Phase 2 Completed 31 enrolled Emory University ALS Association · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, 15-month study evaluating the effect of immunosuppression treatment on the rate of change on the ALS Functional Rating Scale (Revised) (ALSFRS-R) score in up to 33 subjects with Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start: 2013-10
Primary completion: 2016-01
Completion: 2016-01

Publications

Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):242-249. doi: 10.1080/21678421.2017.1421666. Epub 2018 Jan 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Basiliximab	Monoclonal antibody	20 mg	Intravenous
Background	Methylprednisolone	Other / unclassified	125 mg	Intravenous
Background	Mycophenolate Mofetil	Small molecule	1000 mg	Oral
Background	Prednisone	Other / unclassified	10 mg	Oral
Background	Tacrolimus	Small molecule	5 mg	Oral

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Summary

Timeline

Publications

Drugs

Indications